Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Deucravacitinib in the treatment of psoriasis
Tomás Estevinho, Ana Maria Lé, Tiago Torres
Journal of Dermatological Treatment (2022) Vol. 34, Iss. 1
Open Access | Times Cited: 24

Showing 24 citing articles:

Emerging Oral Therapies for the Treatment of Psoriasis: A Review of Pipeline Agents
Anastasia Drakos, Tiago Torres, Ronald Vender
Pharmaceutics (2024) Vol. 16, Iss. 1, pp. 111-111
Open Access | Times Cited: 11
Effectiveness and Safety of Deucravacitinib for the Management of Psoriasis: A Review of the Current Literature
Luca Potestio, Angelo Ruggiero, Gabriella Fabbrocini, et al.
Psoriasis Targets and Therapy (2023) Vol. Volume 13, pp. 19-26
Open Access | Times Cited: 11
Novel anti-psoriatic nanostructured lipid carriers for the cutaneous delivery of luteolin: A comprehensive in-vitro and in-vivo evaluation
Shymaa Hatem, Maha El-Kayal
European Journal of Pharmaceutical Sciences (2023) Vol. 191, pp. 106612-106612
Open Access | Times Cited: 11
Exploring the effect of deucravacitinib in patients with palmoplantar pustular psoriasis
David A. De Luca, Cristian Papara, Tomasz Hawro, et al.
Journal of Dermatological Treatment (2024) Vol. 35, Iss. 1
Open Access | Times Cited: 4
Current and emerging prospects in the psoriatic treatment
Rutuja Vilas Nikam, M Gowtham, Pratiksha Sanjay More, et al.
International Immunopharmacology (2023) Vol. 120, pp. 110331-110331
Closed Access | Times Cited: 10
Novel therapies in SLE treatment: A literature review
Jakub Mastalerz, Alicja Dąbrowska, Wojciech Plizga, et al.
Advances in Clinical and Experimental Medicine (2025) Vol. 34, Iss. 11
Open Access
Targeting IL‐23 with Small Molecule Inhibitors: A New Horizon In Psoriasis Therapy
Raghad Sharbaji, Pınar Si̇yah
ChemistrySelect (2025) Vol. 10, Iss. 8
Closed Access
The emerging role of neutrophil extracellular traps in autoimmune and autoinflammatory diseases
Liuting Zeng, Xiang Wang, Wei Xiao, et al.
MedComm (2025) Vol. 6, Iss. 3
Open Access
Adverse Events Associated with Apremilast and Deucravacitinib for Psoriasis: A Pharmacovigilance Study Based on the FAERS Database
Y. Xu, X LIU, Linghong Guo, et al.
Clinical Cosmetic and Investigational Dermatology (2025) Vol. Volume 18, pp. 1121-1135
Open Access
Therapeutic Potential of Targeting the JAK/STAT Pathway in Psoriasis: Focus on TYK2 Inhibition
Martina Dragotto, Martina D’Onghia, Emanuele Trovato, et al.
Journal of Clinical Medicine (2024) Vol. 13, Iss. 11, pp. 3091-3091
Open Access | Times Cited: 3
A comprehensive review of new small molecule drugs approved by the FDA in 2022: Advance and prospect
Yi‐Ru Bai, Xin Yang, Ken Chen, et al.
European Journal of Medicinal Chemistry (2024) Vol. 277, pp. 116759-116759
Closed Access | Times Cited: 3
Separation and characterization of hydrolytic degradation product of deucravacitinib by validated high‐performance liquid chromatography method and liquid chromatography‐mass spectrometry
Vijaya Madhyanapu Golla, Rahul Khemchandani, Sowmya Chaganti, et al.
Separation Science Plus (2024) Vol. 7, Iss. 5
Closed Access | Times Cited: 2
Comparative efficacy and safety of JAK/TYK2 inhibitors and other oral drugs for moderate-to-severe plaque psoriasis: A systematic review and network meta-analysis
Yaxuan Zheng, Yue Han, Jincong Chen, et al.
Indian Journal of Dermatology Venereology and Leprology (2024) Vol. 90, pp. 590-598
Open Access | Times Cited: 2
Intradermal Injection of a Thermoresponsive Polymeric Dexamethasone Prodrug (ProGel-Dex) Ameliorate Dermatitis in an Imiquimod (IMQ)-Induced Psoriasis-like Mouse Model
Haochen Jiang, Xin Fu, Gang Zhao, et al.
Molecular Pharmaceutics (2024) Vol. 21, Iss. 10, pp. 4995-5004
Closed Access | Times Cited: 2
Development of selective heterocyclic PDE4 inhibitors for treatment of psoriasis
Gang Li, Dengqin He, Xudong Qian, et al.
European Journal of Medicinal Chemistry (2024) Vol. 280, pp. 116930-116930
Closed Access | Times Cited: 2
Deucravacitinib for the treatment of psoriatic arthritis: the evidence so far
Ana María Martins, Ana Maria Lé, Tiago Torres
Drugs in Context (2023) Vol. 12, pp. 1-8
Open Access | Times Cited: 6
Rapid hair regrowth in an alopecia universalis patient with deucravacitinib: A case report
Sarah Oliel, Sarah Moussa, Monica Stanciu, et al.
SAGE Open Medical Case Reports (2023) Vol. 11
Open Access | Times Cited: 4
From Manifestations to Innovations: A Deep Dive into Psoriasis, its Clinical Diversity, Conventional Treatments, and Emerging Therapeutic Paradigms
Sneha Garg, Muskan Dixit, Iresha Malhotra, et al.
International Immunopharmacology (2024) Vol. 143, pp. 113508-113508
Closed Access | Times Cited: 1
Design, Synthesis, and Biological Evaluation of New Selective PDE4 Inhibitors for Topical Treatment of Psoriasis
Dengqin He, Gang Li, Jia‐Qiang Wu, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 22, pp. 20353-20371
Closed Access | Times Cited: 1
Safety and Efficacy of Dual TYK2 Inhibitor and Monoclonal Antibody Therapy for Psoriasis and Psoriatic Arthritis
Sophie Guénin, E.D. Andrews, Mark Lebwohl
British Journal of Dermatology (2023) Vol. 190, Iss. 3, pp. 451-453
Closed Access | Times Cited: 1
Long-term therapy with itolizumab is safe and effective for patients with moderate to severe psoriasis: Results from an expanded-access program
Leopoldina Falcón Lincheta, Yaimarelis Saumell Nápoles, Olaine Regla Gray Lovio, et al.
International Immunopharmacology (2024) Vol. 134, pp. 112225-112225
Closed Access
Differential Effect of JAK1/2 and TYK2 Inhibitors on Type III Interferon Induced Antiviral Defence in Human Intestinal Epithelial Cells
Martha A. Castro, Emma Ringqvist, Anirudra Parajuli, et al.
Immune system (2024), pp. 1-13
Open Access
Psoriasis and Diabetes
David A. De Luca, Diamant Thaçi
Springer eBooks (2024), pp. 211-258
Closed Access
Psoriasis part 1 – clinical picture, pathogenesis, systemic treatment
Bogusława Pietrzak, Ewa Zwierzyńska, Emilia Hytroś
Farmacja Polska (2023) Vol. 79, Iss. 2, pp. 91-100
Open Access
Psoriasis: eine Systemerkrankung mit multiplen Behandlungsoptionen
Paloma Seidel, Nina Magnolo
ästhetische dermatologie & kosmetologie (2023) Vol. 15, Iss. 4, pp. 34-41
Closed Access
Page 1

Scroll to top